Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
AAV8 mediated expression of shRNA targeting soluble epoxide hydrolase suppresses choroidal neovascularization
Author Affiliations & Notes
  • Bomina Park
    Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Sheik Pran Babu Sardar Pasha
    Ophthalmology, Indiana University School of Medicine, Indiana, United States
  • Kamakshi Sishtla
    Ophthalmology, Indiana University School of Medicine, Indiana, United States
  • Timothy William Corson
    Ophthalmology, Indiana University School of Medicine, Indiana, United States
    Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Footnotes
    Commercial Relationships   Bomina Park, None; Sheik Pran Babu Sardar Pasha, None; Kamakshi Sishtla, None; Timothy Corson, 15/889,464 (P), Biomotiv (F)
  • Footnotes
    Support  Indiana Center for Biomedical Innovation, Biomotiv, Retina Research Foundation, Carl Marshall Reeves & Mildred Almen Reeves Foundation, Indiana CTSI (UL1TR002529)
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4343. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bomina Park, Sheik Pran Babu Sardar Pasha, Kamakshi Sishtla, Timothy William Corson; AAV8 mediated expression of shRNA targeting soluble epoxide hydrolase suppresses choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4343.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Soluble epoxide hydrolase (sEH), encoded by Ephx2, metabolizes epoxy fatty acids into diols. We identified sEH as a target of a novel antiangiogenic small molecule, SH-11037, and showed that intravitreal chemical inhibition of sEH suppresses choroidal neovascularization (CNV). Other studies reported that systemic knockout or inhibition of sEH also reduces CNV. However, ocular tissue specific knockdown of sEH and gene therapy approaches to target sEH to treat CNV have not been investigated to date. Here, we examined antiangiogenic effects of sEH knockdown using an adeno-associated virus (AAV) serotype 8 vector expressing shRNA against sEH, delivered intravitreally in the mouse laser-induced CNV model.

Methods : AAV8 vectors (0.5 µl of 1x1011 gc/µl) with CMV promoter-driven Ephx2 shRNA, scrambled control shRNA (each with mCherry reporter) or 0.5 µl of vehicle (PBS) were injected intravitreally in 7 week old C57BL/6J male mice. After 7 days, mice were treated with laser to induce CNV. Transduction level (mCherry fluorescence) and neovascular volume were assessed by weekly fundoscopy and optical coherence tomography. On day 14 post laser, retina and choroid tissue of each treatment group were harvested for choroidal flatmounts, cryosectioning, protein, and RNA analyses. Expression of sEH and relevant targets in treated retina and choroid tissue was assessed by qPCR and immunoblot. CNV lesion volume was calculated using OCT measurements and by confocal Z-stack imaging of choroidal flatmounts stained with isolectin GS-IB4.

Results : Fluorescence fundoscopy showed efficient viral transduction and microscopic assessment revealed transduced cells localized in the photoreceptors and RPE. sEH expression was reduced in retina and choroid at protein and mRNA levels. Compared to vehicle and AAV8-scrambled shRNA controls, AAV8-Ephx2 shRNA delivery significantly reduced CNV. In addition, gene expression analysis showed reduced Vegfc and inflammatory markers Tnfα, Il1β, and Vcam1 but increased cytoprotective Hmox1 in the AAV8-Ephx2 shRNA treatment group compared to scrambled control.

Conclusions : Tissue specific knockdown of sEH in the eye inhibits CNV. Thus, depletion of sEH phenocopies the antiangiogenic effects seen with small molecule inhibitors, further demonstrating sEH as a promising therapeutic target in the treatment of CNV associated with wet AMD.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×